Hacker News
new
|
past
|
comments
|
ask
|
show
|
jobs
|
submit
login
jojobas
3 months ago
|
parent
|
context
|
favorite
| on:
Goldman Sachs asks in biotech Report: Is curing pa...
Obviously a hemophilia cure is a bad investment, recurring lifelong hemophilia treatment is very much more attractive.
Guidelines
|
FAQ
|
Lists
|
API
|
Security
|
Legal
|
Apply to YC
|
Contact
Search:
